CA3221964A1 - Nitroxoline for use in the treatment of cutaneous neurofibroma - Google Patents

Nitroxoline for use in the treatment of cutaneous neurofibroma Download PDF

Info

Publication number
CA3221964A1
CA3221964A1 CA3221964A CA3221964A CA3221964A1 CA 3221964 A1 CA3221964 A1 CA 3221964A1 CA 3221964 A CA3221964 A CA 3221964A CA 3221964 A CA3221964 A CA 3221964A CA 3221964 A1 CA3221964 A1 CA 3221964A1
Authority
CA
Canada
Prior art keywords
composition
nitroxoline
use according
cells
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3221964A
Other languages
English (en)
French (fr)
Inventor
David Brown
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Healx Ltd
Original Assignee
Healx Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Healx Ltd filed Critical Healx Ltd
Publication of CA3221964A1 publication Critical patent/CA3221964A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3221964A 2021-06-09 2022-06-09 Nitroxoline for use in the treatment of cutaneous neurofibroma Pending CA3221964A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2108224.3 2021-06-09
GBGB2108224.3A GB202108224D0 (en) 2021-06-09 2021-06-09 Treatment
PCT/GB2022/051442 WO2022258972A1 (en) 2021-06-09 2022-06-09 Nitroxoline for use in the treatment of cutaneous neurofibroma

Publications (1)

Publication Number Publication Date
CA3221964A1 true CA3221964A1 (en) 2022-12-15

Family

ID=76838879

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3221964A Pending CA3221964A1 (en) 2021-06-09 2022-06-09 Nitroxoline for use in the treatment of cutaneous neurofibroma

Country Status (12)

Country Link
US (1) US20240261276A1 (enExample)
EP (1) EP4351576A1 (enExample)
JP (1) JP2024520690A (enExample)
KR (1) KR20240024175A (enExample)
CN (1) CN117769419A (enExample)
AU (1) AU2022290019A1 (enExample)
BR (1) BR112023025789A2 (enExample)
CA (1) CA3221964A1 (enExample)
GB (1) GB202108224D0 (enExample)
IL (1) IL309177A (enExample)
MX (1) MX2023014530A (enExample)
WO (1) WO2022258972A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202116743D0 (en) * 2021-11-19 2022-01-05 Healx Ltd Treatment
GB202218460D0 (en) * 2022-12-08 2023-01-25 Healx Ltd Treatment

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2970128B1 (en) * 2013-03-15 2019-12-04 Asieris Pharmaceutical Technologies Co., Ltd. Base addition salts of nitroxoline and uses thereof
CA3287905A1 (en) * 2016-10-14 2025-11-29 Wake Forest University Health Sciences Compositions, cell constructs, and methods of making and using the same
EP3883552B1 (en) * 2018-11-20 2025-04-09 NFlection Therapeutics, Inc. Cyanoaryl-aniline compounds for treatment of dermal disorders
CN112402388A (zh) * 2019-08-05 2021-02-26 江苏亚虹医药科技股份有限公司 一种用于治疗膀胱癌的口服固体制剂及其制备方法

Also Published As

Publication number Publication date
MX2023014530A (es) 2024-04-10
US20240261276A1 (en) 2024-08-08
JP2024520690A (ja) 2024-05-24
BR112023025789A2 (pt) 2024-02-27
WO2022258972A1 (en) 2022-12-15
CN117769419A (zh) 2024-03-26
EP4351576A1 (en) 2024-04-17
AU2022290019A1 (en) 2023-12-14
IL309177A (en) 2024-02-01
KR20240024175A (ko) 2024-02-23
GB202108224D0 (en) 2021-07-21

Similar Documents

Publication Publication Date Title
JP5424923B2 (ja) 乾癬及び他の皮膚疾患治療におけるシクロパミンの使用
Huang et al. Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment
KR100891568B1 (ko) 나트륨 채널 차단 화합물인 테트로도톡신의 무통 제공 방법
JP2006512281A (ja) 乾癬及び他の皮膚疾患治療におけるシクロパミンの使用
CN103533930A (zh) 用于治疗神经性疼痛的大麻素类化合物
US20240261276A1 (en) Nitroxoline for use in the treatment of cutaneous neurofibroma
CN113194946B (zh) 用于治疗血管性埃勒斯-当洛斯综合征和有关障碍的组合物和方法
US20250000852A1 (en) Nitroxoline for use in the treatment or prevention of a plexiform neurofibroma
JPWO2021066144A1 (ja) ヘテロシクリデンアセトアミド誘導体含有医薬
EP4171553A1 (en) Mmp-9 and mmp-12 inhibition for treating spinal cord injury or related injury to neurological tissue
WO2019197632A1 (en) Treatment of fragile x syndrome
US12599617B2 (en) Methods of treating head and neck cancers with hemp extract
Nabiya et al. Identification of Fungal Bioactive Compounds Targeting MMP-9 for Endometriosis-An In silico Approach
CN108175769A (zh) 土贝母苷甲在制备治疗类风湿性关节炎药物中的应用
CA3149702A1 (en) Treatment of fragile x syndrome
CN102258512A (zh) Ag490在预防和治疗腹主动脉瘤的用途
AU2023391325A1 (en) Nitroxoline for use in the treatment or prevention of a malignant peripheral nerve sheath tumour
WO2010120203A1 (ru) Применение органических красителей в качестве обезболивающих средств
HK1174565B (en) Method of treating scars and ss-catenin-mediated disorders using nefopam compounds

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20240925

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D123 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIOR ART DISCLOSURE DETERMINED COMPLIANT

Effective date: 20250114

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250114

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250606

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250606

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20260514

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260514